ASX-LISTED medicinal cannabis research company Zelda Therapeutics has announced that it will be partnering with the Children's Hospital of Philadelphia (CHOP) in the US to run initial observational trials on children with autism spectrum disorder.
Zelda said the arrangement would allow the company to utilise CHOP's extensive resources to measure the effectiveness of medicinal cannabis as a possible treatment for children with autism.
Data generated from the initial study will contribute to evaluation of the extensive positive anecdotal evidence that already exists while providing the foundational knowledge needed to develop new safe, effective and affordable cannabinoid based medicines.
As one of the most prevalent neurological conditions in children, with one in 160 affected globally, current autism treatments present with a "number of serious side effects" and there is no single recognised therapy.
Zelda is also researching with Complutense University in Madrid, Spain, as well as the Australian Telethon Kids and Curtin University.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 17
